Cart
sales@molnova.com
Roxifiban acetate
CAS No. 176022-59-6
Roxifiban acetate( —— )
Catalog No. M34020 CAS No. 176022-59-6
Roxifiban acetate（DMP 754 acetate） is a potent GP IIb / IIIa antagonist that exhibits antiplatelet aggregation activity via immune mediation and can be used in the study of human thrombocytopenia.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 787 | Get Quote |
|
| 5MG | 1112 | Get Quote |
|
| 25MG | 1766 | Get Quote |
|
| 50MG | 2190 | Get Quote |
|
| 100MG | 2790 | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameRoxifiban acetate
-
NoteResearch use only, not for human use.
-
Brief DescriptionRoxifiban acetate（DMP 754 acetate） is a potent GP IIb / IIIa antagonist that exhibits antiplatelet aggregation activity via immune mediation and can be used in the study of human thrombocytopenia.
-
DescriptionRoxifiban acetate（DMP 754 acetate） is a potent GP IIb / IIIa antagonist that exhibits antiplatelet aggregation activity via immune mediation and can be used in the study of human thrombocytopenia.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayCell Cycle/DNA Damage
-
TargetIntegrin
-
RecptorIntegrin
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number176022-59-6
-
Formula Weight507.54
-
Molecular FormulaC23H33N5O8
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESC(C)(O)=O.C(C(NC[C@H](NC(OCCCC)=O)C(OC)=O)=O)[C@H]1CC(=NO1)C2=CC=C(C(=N)N)C=C2
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
Cyclo(-RGDfK)
A RGD pipetide, potent and selective αvβ3 integrin inhibitor with Kd of 41.7 nM.
-
Tadocizumab
Tadocizumab (C4G1) is a humanized monoclonal antibody targeting integrin αIIbβ3 with antiplatelet and antithrombotic activity that blocks the platelet αIIbβ3 integrin interac- with brinogen and bronectin, and can be used in the study of cardiovascular disease.
-
OSU-T315
A novel potent, orally active ILK (integrin-linked kinase) inhibitor with IC50 of 0.6 uM.
